Plk1 regulates liver tumor cell death by phosphorylation of TAp63

Oncogene

Volumn 28, Issue 41, 2009, Pages 3631-3641

  Komatsu, S ^a,b   Takenobu, H ^a   Ozaki, T ^a   Ando, K ^a   Koida, N ^a   Suenaga, Y ^a   Ichikawa, T ^a   Hishiki, T ^b   Chiba, T ^b   Iwama, A ^b   Yoshida, H ^b   Ohnuma, N ^b   Nakagawara, A ^a   Kamijo, T ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Apoptosis; P63; Phosphorylation; Plk1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; POLO LIKE KINASE 1; PROTEIN P53; PROTEIN P63; PUMA PROTEIN; SERINE;

ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; LIVER TUMOR; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SERINE; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 70350057293     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.216     Document Type: Article

References (44)

1. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-25561.
2. Blandino G, Dobbelstein M. (2004). p73 and p63: why do we still need them? Cell Cycle 3: 886-894.
3. Bruix J, Llovet JM. (2002). Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524.
4. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M et al. (2007). TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6: 274-285.
5. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y et al. (2006). p63 is upstream of IKK alpha in epidermal development. J Cell Sci 119: 4617-4622.
6. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A et al. (2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251.
7. Eckerdt F, Strebhardt K. (2006). Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 66: 6895-6898.
8. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
9. Ghioni P, D'Alessandra Y, Mansueto G, Jaffray E, Hay RT, La Mantia G et al. (2005). The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4: 183-190.
10. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. (2005). TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458-2471.
11. Huang YP, Wu G, Guo Z, Osada M, Fomenkov T, Park HL et al. (2004). Altered sumoylation of p63alpha contributes to the split-hand/foot malformation phenotype. Cell Cycle 3: 1587-1596.
12. Ichikawa T, Suenaga Y, Koda T, Ozaki T, Nakagawara A. (2008). TAp63-dependent induction of growth differentiation factor 15 (GDF15) plays a critical role in the regulation of keratinocyte differentiation. Oncogene 27: 409-420.
13. Kato S, Shimada A, Osada M, Ikawa S, Obinata M, Nakagawara A et al. (1999). Effects of p51/p63 missense mutations on transcrip-tional activities of p53 downstream gene promoters. Cancer Res 59: 5908-5911.
14. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A et al. (2003). Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9: 5501-5507.
15. Koida N, Ozaki T, Yamamoto H, Ono S, Koda T, Ando K et al. (2008). Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 283: 8555-8563.
16. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. (2004). p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131.
17. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
18. Lu LY, Wood JL, Minter-Dykhouse K, Ye L, Saunders TL, Yu X et al. (2008). Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 28: 6870-6876.
19. MacPartlin M, Zeng SX, Lu H. (2008). Phosphorylation and stabilization of TAp63gamma by IkappaB kinase-beta. J Biol Chem 283: 15754-15761.
20. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME et al. (2003). Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63: 7113-7121.
21. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
22. Moll UM, Slade N. (2004). p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386.
23. Montesano R, Hainaut P, Wild CP. (1997). Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89: 1844-1851.
24. Nakajima H, Toyoshima-Morimoto F, Taniguchi E, Nishida E. (2003). Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 278: 25277-25280.
25. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G et al. (2006). Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev 20: 1028-1042.
26. Parkin DM, Bray F, Ferlay J, Pisani P. (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. (Pubitemid 32911406)
27. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron de Fromentel C. (2005). The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene 24: 512-519.
28. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56.
29. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C et al. (2002). The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 277: 719-724.
30. Shen HM, Ong CN. (2004). Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 366: 23-44.
31. Shieh SY, Ikeda M, Taya Y, Prives C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
32. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2: 672-676.
33. Strebhardt K, Ullrich A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330.
34. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. (2006). p63 protects the female germ line during meiotic arrest. Nature 444: 624-628.
35. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP et al. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161: 1199-1206.
36. Van Vugt MA, Smits VA, Klompmaker R, Medema RH. (2001). Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM-or ATR-dependent fashion. J Biol Chem 276: 41656-41660.
37. Vousden KH, Lu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
38. Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. (2005). Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle 4: 710-716.
39. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. (2003). The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23: 2264-2276.
40. Winkles JA, Alberts GF. (2005). Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260-266.
41. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y et al. (2004). Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23: 5901-5911.
42. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
43. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
44. Zhou J, Zhang Y. (2008). Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 7: 1360-1370.